Faeth Therapeutics, Inc. lost $16.72 per diluted share in fiscal year 2025. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Faeth Therapeutics, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$16.72
Ticker history: SNSE became
FTH
(Faeth Therapeutics, Inc.) on .
Earlier news and filings retain their original names and dates.
View SNSE history.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Faeth Therapeutics, Inc. lost $16.72 per diluted share in fiscal year 2025.
Across the 6 fiscal years this page covers, Faeth Therapeutics, Inc. (FTH) diluted earnings per share went from -$12.53 in fiscal year 2020 to -$16.72 in fiscal year 2025.
Faeth Therapeutics, Inc. (FTH) reported -$0.79 in diluted earnings per share in Q3 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Faeth Therapeutics, Inc. (FTH) reported on that line in every period on record.
